BRPI0822206A2 - Formulação líquida para deferiprona com um sabor agradável. - Google Patents

Formulação líquida para deferiprona com um sabor agradável.

Info

Publication number
BRPI0822206A2
BRPI0822206A2 BRPI0822206-1A BRPI0822206A BRPI0822206A2 BR PI0822206 A2 BRPI0822206 A2 BR PI0822206A2 BR PI0822206 A BRPI0822206 A BR PI0822206A BR PI0822206 A2 BRPI0822206 A2 BR PI0822206A2
Authority
BR
Brazil
Prior art keywords
deferiprone
liquid formulation
pleasant taste
pleasant
taste
Prior art date
Application number
BRPI0822206-1A
Other languages
English (en)
Inventor
Michael Spino
Anita Hui
Cihua Yang
Mohammed N Kabir
Original Assignee
Apotex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Technologies Inc filed Critical Apotex Technologies Inc
Publication of BRPI0822206A2 publication Critical patent/BRPI0822206A2/pt
Publication of BRPI0822206B1 publication Critical patent/BRPI0822206B1/pt
Publication of BRPI0822206B8 publication Critical patent/BRPI0822206B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0822206A 2008-04-25 2008-04-25 formulação líquida para deferiprona com um sabor agradável. BRPI0822206B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2008/000784 WO2009129592A1 (en) 2008-04-25 2008-04-25 Liquid formulation for deferiprone with palatable taste

Publications (3)

Publication Number Publication Date
BRPI0822206A2 true BRPI0822206A2 (pt) 2015-06-23
BRPI0822206B1 BRPI0822206B1 (pt) 2019-03-19
BRPI0822206B8 BRPI0822206B8 (pt) 2021-05-25

Family

ID=41216357

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822206A BRPI0822206B8 (pt) 2008-04-25 2008-04-25 formulação líquida para deferiprona com um sabor agradável.

Country Status (24)

Country Link
US (1) US8703156B2 (pt)
EP (1) EP2268282B1 (pt)
KR (1) KR101490721B1 (pt)
CN (1) CN102014904B (pt)
AP (1) AP2010005454A0 (pt)
AU (1) AU2008355464C1 (pt)
BR (1) BRPI0822206B8 (pt)
CA (1) CA2722393A1 (pt)
CR (1) CR11744A (pt)
CY (1) CY1116146T1 (pt)
DK (1) DK2268282T3 (pt)
EA (1) EA022751B1 (pt)
ES (1) ES2539414T3 (pt)
HR (1) HRP20150083T1 (pt)
IL (1) IL208876A (pt)
MX (1) MX2010011701A (pt)
NZ (1) NZ588602A (pt)
PL (1) PL2268282T3 (pt)
PT (1) PT2268282E (pt)
RS (1) RS53689B1 (pt)
SI (1) SI2268282T1 (pt)
UA (1) UA102254C2 (pt)
WO (1) WO2009129592A1 (pt)
ZA (1) ZA201008374B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
AU2010268666B2 (en) 2009-07-03 2014-07-24 Apotex Inc. Fluorinated derivatives of 3-Hydroxypyridin-4-ones
CN104955482A (zh) 2012-11-12 2015-09-30 希普拉有限公司 包含地拉罗司和去铁酮的固定剂量的药物组合物
WO2017199073A1 (en) * 2016-05-18 2017-11-23 Karimian, Khashayar Effervescent deferiprone tabelt
GR1009462B (el) * 2017-10-05 2019-02-15 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμο φαρμακευτικο διαλυμα με συγκαλυμμενη γευση
PT3684344T (pt) 2017-10-25 2025-08-04 Chiesi Farm Spa Comprimidos de deferiprona de libertação retardada e métodos de utilização dos mesmos
MX2021010945A (es) * 2019-03-14 2021-10-13 Neuroenergy Ventures Inc Formula que enmascara el sabor para compuestos de cuerpos cetonicos.
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
NL2024161B1 (en) * 2019-11-05 2021-07-20 Mperium B V Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
WO2024023785A1 (en) 2022-07-29 2024-02-01 Berlia Sushma Paul A stable pharmaceutical oral liquid formulation of an antispasmodic agent

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918402A (en) * 1958-07-29 1959-12-22 Dodge Chem Co Bactericidal-fungicidal compositions
BE639493A (pt) * 1962-12-20
CA1095921A (en) 1976-08-02 1981-02-17 Thomas M. Brennan Preparation of gamma-pyrones
GB8308054D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8308055D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
USRE34313E (en) * 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
GB8329043D0 (en) 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
EP0336369A1 (en) 1988-04-04 1989-10-11 E.R. Squibb & Sons, Inc. 3-Acylamino-1-[[[(substituted sulfonyl)amino]carbonyl]amino]2-azetidinones
DE3826846A1 (de) 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
JPH0714872B2 (ja) * 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
GB9100465D0 (en) 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions
US5624807A (en) * 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
NO941358L (no) * 1993-04-16 1994-10-17 Mcneil Ppc Inc Vandig farmasöytisk suspensjon og fremgangsmåte for fremstilling derav
CA2181463A1 (en) 1994-01-31 1995-08-03 Fu-Ning Fung Method of synthesizing gamma pyrones
EP0754039A4 (en) * 1994-04-08 2002-07-17 Procter & Gamble Methods of using iron chelating compounds to reduce free radical damage in mammals
AU3154895A (en) * 1994-08-01 1996-03-04 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
JPH0925234A (ja) 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
GB9711093D0 (en) * 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
KR100764520B1 (ko) 1998-08-28 2007-10-09 에자이 알앤드디 매니지먼트 가부시키가이샤 고미 등을 경감한 의약조성물
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
CA2272971C (en) * 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
IL130324A0 (en) * 1999-06-07 2000-06-01 Yeda Res & Dev Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) * 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
MXPA03008056A (es) * 2001-03-05 2004-10-15 Johnson & Johnson Composiciones farmaceuticas liquidas con sabor oculto.
WO2003075910A1 (en) 2002-03-08 2003-09-18 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
CA2478411C (en) * 2002-03-12 2010-09-28 Bristol-Myers Squibb Company Palatable oral suspension and method
AU2003251920A1 (en) * 2002-07-12 2004-02-02 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
JP4757024B2 (ja) * 2002-11-07 2011-08-24 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド 神経保護鉄キレート剤及びそれを含む医薬組成物
DE10336497B4 (de) 2003-08-08 2007-04-05 Freie Universität Berlin Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen
EP1742535A4 (en) * 2004-05-06 2008-10-15 Cydex Pharmaceuticals Inc MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CA2568134A1 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20060093630A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
RU2008137604A (ru) * 2006-02-22 2010-03-27 Арнольд МЮННИК (FR) Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа
WO2008116301A1 (en) 2007-03-28 2008-10-02 Apotex Technologies Inc. Fluorinated derivatives of deferiprone
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds

Also Published As

Publication number Publication date
PT2268282E (pt) 2015-02-05
CY1116146T1 (el) 2017-02-08
AU2008355464A1 (en) 2009-10-29
CR11744A (es) 2011-01-10
US20110039897A1 (en) 2011-02-17
ZA201008374B (en) 2012-01-25
BRPI0822206B8 (pt) 2021-05-25
CA2722393A1 (en) 2009-10-29
EP2268282A4 (en) 2011-06-22
RS53689B1 (sr) 2015-04-30
US8703156B2 (en) 2014-04-22
KR20100135316A (ko) 2010-12-24
EP2268282A1 (en) 2011-01-05
EP2268282B1 (en) 2014-10-29
CN102014904A (zh) 2011-04-13
MX2010011701A (es) 2010-12-06
AU2008355464B2 (en) 2014-04-10
KR101490721B1 (ko) 2015-02-06
EA022751B1 (ru) 2016-02-29
IL208876A0 (en) 2011-01-31
BRPI0822206B1 (pt) 2019-03-19
ES2539414T3 (es) 2015-06-30
AU2008355464C1 (en) 2014-11-20
EA201071235A1 (ru) 2011-06-30
NZ588602A (en) 2012-08-31
IL208876A (en) 2015-02-26
WO2009129592A1 (en) 2009-10-29
PL2268282T3 (pl) 2015-04-30
AP2010005454A0 (en) 2010-12-31
CN102014904B (zh) 2013-02-06
HRP20150083T1 (hr) 2015-03-13
HK1152871A1 (en) 2012-03-16
DK2268282T3 (en) 2014-11-24
SI2268282T1 (sl) 2015-01-30
UA102254C2 (ru) 2013-06-25

Similar Documents

Publication Publication Date Title
BRPI0822206A2 (pt) Formulação líquida para deferiprona com um sabor agradável.
BRPI0814863A2 (pt) Dispensador de bomba manual.
BRPI0912336A2 (pt) dispensador de bebidas.
BRPI0912335A2 (pt) dispensador de bebidas.
ES1070574Y (es) Molinillo - dispensador de cafe
BRPI0814805A2 (pt) Emulsões duplas estáveis
BRPI0918430A2 (pt) 4-fenil-1h-pirazóis inseticidas.
BRPI0920521A2 (pt) combinação farmacêutica
UA18940S (uk) Шоколад
BRPI0911353A2 (pt) recipiente para recarga
BRPI0906579A2 (pt) Válvula para dispensador decorativo
BRPI0913873A2 (pt) recipiente para dose única
DK2114143T3 (da) Flydende sulfonylurea-herbicidformuleringer
BRPI0925077A2 (pt) Conjunto dispensador.
FR2933381B1 (fr) Distributeur a tete amovible.
DE112008003198A5 (de) Schmierstoffgeber
EP3115072C0 (en) BLOOD TANK
PL3005986T3 (pl) Infuzja leków
BRPI0921654A2 (pt) formulação farmacêutica
IT1393854B1 (it) Dispenser.
BRPI0814063A2 (pt) Cabeça dispensadora
DK2170297T3 (da) Duloxetinformulering
IT1395956B1 (it) Dispenser.
BRPI0807698A2 (pt) Inalador com dosador
DK2323926T3 (da) Dispenser

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/03/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: APOTEX INC. (CA)

B25A Requested transfer of rights approved

Owner name: CHIESI FARMACEUTICI S.P.A. (IT)